BiotechTube

NAL ER + Placebo + NAL ER + NAL ER

Phase 2Completed
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Idiopathic Pulmonary Fibrosis

Conditions

Idiopathic Pulmonary Fibrosis

Trial Timeline

Feb 6, 2024 → Apr 24, 2025

NCT ID
NCT05964335

About NAL ER + Placebo + NAL ER + NAL ER

NAL ER + Placebo + NAL ER + NAL ER is a phase 2 stage product being developed by Trevi Therapeutics for Idiopathic Pulmonary Fibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT05964335. Target conditions include Idiopathic Pulmonary Fibrosis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05964335Phase 2Completed

Competing Products

20 competing products in Idiopathic Pulmonary Fibrosis

See all competitors
ProductCompanyStageHype Score
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
47
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + PlaceboRein TherapeuticsPhase 1
25
LTI-03 + PlaceboRein TherapeuticsPhase 1
25
LTI-03 + PlaceboRein TherapeuticsPhase 2
44
Tirzepatide + Tirzepatide PlaceboEli LillyApproved
85
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
Zimura + EyleaAstellas PharmaPhase 2
52
Avacincaptad PegolAstellas PharmaPhase 2
52
Rituximab + cyclosporineSun PharmaceuticalPhase 3
77
E5501EisaiPhase 1
33
E5501 + Drug: E5501EisaiPhase 1
33
E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with foodEisaiPhase 1
33
Eltrombopag + Avatrombopag + Standard of careEisaiPhase 3
77
Placebo + Avatrombopag tabletsEisaiPhase 2
52
PerampanelEisaiPre-clinical
23
Blinded (placebo) + Open Label (Avatrombopag tablets) + Blinded (Avatrombopoag tablets)EisaiPhase 2
52
Istradefylline 20 mg or 40 mgKyowa KirinPhase 3
77

Other Products from Trevi Therapeutics

nalbuphine HCl ER tablets 90 mg BID + nalbuphine HCl ER tablets 180 mg BID + Placebo tablets BIDPhase 2/3
60
nalbuphine HCl ERPhase 2/3
60
nalbuphine HCl ERPhase 2/3
60
nalbuphine HCl ER tablets 60 mg BID + nalbuphine HCl ER tablets 120mg BID + Placebo tablets BIDPhase 2/3
60
Nalbuphine ER Tablets + Placebo TabletsPhase 2/3
60